AI Article Synopsis

  • The study investigates the levels of various soluble immune mediators in gastric cancer (GC) patients compared to healthy controls, focusing on potential therapeutic targets for treatment.
  • Results indicate low levels of sPD-1, sPD-L2, and sGal9, while levels of sPD-L1, sTIM-3, sGITR, and sGITRL were higher in GC patients, with variations based on cancer stages and specific tumor locations.
  • Findings suggest a potential link between certain soluble mediators (sPD-1, sTIM-3, sGal9) and disease progression, as well as the association of low sGITR with increased mortality within the first

Article Abstract

Background: Co-inhibitor and co-stimulator mediators trigger actions that result in immunological homeostasis and are being evaluated as potential therapeutic targets in gastric cancer (GC).

Objective: To evaluate the soluble levels of sPD-1, sPD-L1, sPD-L2, sTIM-3, sGal9, sGITR, and sGITRL in GC patients.

Methods: The cross-sectional study was carried out at the Hospital de Cancer de Pernambuco, Brazil between 2017 and 2018. A total of 74 GC patients and 30 healthy controls were included.

Results: Low levels of sPD1 (p = 0.0179), sPDL2 (p = 0.0003), and sGal9 (p < 0.0001), and higher levels of sPDL1 (p = 0.004), sTIM-3 (p = 0.0072), sGITR (p = 0.0179), and sGITRL (p = 0.0055) compared to the control group. High sPD-1, sTIM-3, and sGal9 levels in stage IV compared I/II and III (p < 0.05). High sPDL1, sGal9, and sGITRL levels in esophagogastric junction compared to body and Pylorus/Antrum groups (p < 0.05). No significant differences were observed in sPD1, sPDL1, sPDL2, sTIM3, sGal9, sGITR, and sGITRL levels between the intestinal, diffuse, and mixed GC groups. Low sGITR levels in GC patients who died within the first 24 months compared to the who survived (p = 0.0332).

Conclusions: There is an association of sPD1, sTIM-3, and sGal9 with disease progression and sGITR with death, these mediators may be potential prognostic biomarkers in GC.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.27747DOI Listing

Publication Analysis

Top Keywords

gastric cancer
8
evaluation soluble
4
soluble co-inhibitors
4
co-inhibitors co-stimulators
4
co-stimulators levels
4
levels immune
4
immune response
4
response gastric
4
cancer background
4
background co-inhibitor
4

Similar Publications

Bimodal In Situ Analyzer for Circular RNA in Extracellular Vesicles Combined with Machine Learning for Accurate Gastric Cancer Detection.

Adv Sci (Weinh)

January 2025

Department of Laboratory Medicine, Guangdong Provincial Key Laboratory of Precision Medical Diagnostics, Guangdong Engineering and Technology Research Center for Rapid Diagnostic Biosensors, Guangdong Provincial Key Laboratory of Single Cell Technology and Application, School of Laboratory Medicine and Biotechnology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, P. R. China.

Circular RNAs in extracellular vesicles (EV-circRNAs) are gaining recognition as potential biomarkers for the diagnosis of gastric cancer (GC). Most current research is focused on identifying new biomarkers and their functional significance in disease regulation. However, the practical application of EV-circRNAs in the early diagnosis of GC is yet to be thoroughly explored due to the low accuracy of EV-circRNAs analysis.

View Article and Find Full Text PDF

Despite substantial advances in the antitumor effects of annonaceous acetogenins (ACGs), the absence of a defined biological action mechanism remains a major barrier to their clinical application. Here, it is found that squamocin effectively depletes both EZH2 and MYC in multiple cancer cell lines, including head and neck squamous cell carcinoma, and gastric and colorectal cancer, demonstrating potent efficacy in suppressing these in vivo tumor models. Through the combination of surface plasmon resonance (SPR), differential scanning fluorimetry (DSF), and cellular thermal shift assay (CETSA), heat shock protein 90α (HSP90α) is identified as the direct binding target of squamocin.

View Article and Find Full Text PDF

Trophoblast glycoprotein (TPBG) plays a significant part in the growth of specific cancers, yet its connection to gastric cancer (GC) remains uncertain. This research seeks to analyse the fluctuation in TPBG levels in GC and evaluate how TPBG expression relates to the prognosis of GC patients. TPBG expression in GC and normal gastric tissues was investigated in The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) database, further extracting the immunohistochemistry images from HPA database and validating by Western blot.

View Article and Find Full Text PDF

Breath analysis is increasingly recognized as a powerful noninvasive diagnostic technique, and a plethora of exhaled volatile biomarkers have been associated with various diseases. However, traditional analytical methodologies are not amenable to high-throughput diagnostic applications at the point of need. An optical spectroscopic technique, surface-enhanced Raman spectroscopy (SERS), mostly used in the research setting for liquid sample analysis, has recently been applied to breath-based diagnostics.

View Article and Find Full Text PDF

Background: Lymphatic metastasis in gastric cancer (GC) profoundly influences its prognosis, but the precise mechanism remains elusive. In this study, we identified the long noncoding RNA MIR181A2HG as being upregulated in GC and associated with LNs metastasis and prognosis.

Methods: The expression of MIR181A2HG in GC was identified through bioinformatics screening analysis and qRT-PCR validation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!